117 related articles for article (PubMed ID: 21317583)
1. Clinical impact and cost of laboratory monitoring need review even in resource-rich setting.
Sayana S; Javanbakht M; Weinstein M; Khanlou H
J Acquir Immune Defic Syndr; 2011 Mar; 56(3):e97-8. PubMed ID: 21317583
[No Abstract] [Full Text] [Related]
2. Reply to "Clinical impact and cost of laboratory monitoring need review even in resource-rich setting".
Fernandez G; Harris S; Frontini M; Clark RA
J Acquir Immune Defic Syndr; 2012 Apr; 59(5):e99-e100. PubMed ID: 22410871
[No Abstract] [Full Text] [Related]
3. Monitoring of highly active antiretroviral therapy in HIV infection.
Walker AS; Gibb DM
Curr Opin Infect Dis; 2011 Feb; 24(1):27-33. PubMed ID: 21150591
[TBL] [Abstract][Full Text] [Related]
4. Impact of the frequency of plasma HIV-1 RNA monitoring on the outcome of antiretroviral therapy.
Chaiwarith R; Praparattanapan J; Nuntachit N; Kotarathitithum W; Sirisanthana T; Supparatpinyo K
Curr HIV Res; 2011 Mar; 9(2):82-7. PubMed ID: 21361862
[TBL] [Abstract][Full Text] [Related]
5. Virological efficacy of a reduced dose of nevirapine in a small cohort of suppressed HIV-1-infected patients.
Lanzafame M; Lattuada E; Cucchetto G; Nicolè S; Concia E; Vento S
J Acquir Immune Defic Syndr; 2015 Apr; 68(4):e59-61. PubMed ID: 25559599
[No Abstract] [Full Text] [Related]
6. Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less.
Bélec L; Bonn JP
Future Microbiol; 2011 Nov; 6(11):1251-60. PubMed ID: 22082287
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
[TBL] [Abstract][Full Text] [Related]
8. HIV therapeutics: points from the recent literature.
Laurence J
AIDS Read; 2003 Jul; 13(7):305, 307. PubMed ID: 12889448
[No Abstract] [Full Text] [Related]
9. The DART trial: 'The doctor's dilemma' revisited.
Nunes EP; Grinsztejn B; Schechter M
J Antimicrob Chemother; 2011 May; 66(5):964-7. PubMed ID: 21393146
[TBL] [Abstract][Full Text] [Related]
10. Raltegravir/nevirapine dual therapy at reduced doses as 'maintenance' treatment in virally suppressed HIV-infected patients.
Lanzafame M; Lattuada E; Rigo F; Nicole S; Cucchetto G; Vento S
AIDS; 2015 Aug; 29(13):1722-3. PubMed ID: 26372286
[No Abstract] [Full Text] [Related]
11. HIV-1 drug resistance at virological failure versus immunological failure among patients failing first-line antiretroviral therapy in a resource-limited setting.
Sungkanuparph S; Win MM; Kiertiburanakul S; Phonrat B; Maek-a-nantawat W
Int J STD AIDS; 2012 May; 23(5):316-8. PubMed ID: 22648883
[TBL] [Abstract][Full Text] [Related]
12. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial.
Maggiolo F; Ripamonti D; Gregis G; Quinzan G; Callegaro A; Suter F
AIDS; 2004 Feb; 18(3):439-46. PubMed ID: 15090796
[TBL] [Abstract][Full Text] [Related]
13. When to start, when to STI (or, groping for the golden moment).
Mascolini M
IAPAC Mon; 2001 Apr; 7(4):114-7, 120-31. PubMed ID: 11700605
[No Abstract] [Full Text] [Related]
14. CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.
Hoffmann CJ; Maritz J; van Zyl GU
Trop Med Int Health; 2016 Feb; 21(2):219-23. PubMed ID: 26584666
[TBL] [Abstract][Full Text] [Related]
15. Baseline HIV RNA and the when to start question: time to stop asking this question?
Mussini C
AIDS; 2006 May; 20(8):1197-8. PubMed ID: 16691072
[No Abstract] [Full Text] [Related]
16. Raltegravir: is a 400 mg once-daily dose enough?
Lanzafame M; Hill A; Lattuada E; Calcagno A; Bonora S
J Antimicrob Chemother; 2010 Mar; 65(3):595-7. PubMed ID: 20071368
[No Abstract] [Full Text] [Related]
17. Therapeutic drug monitoring of antiretroviral therapy.
Rakhmanina NY; van den Anker JN; Soldin SJ
AIDS Patient Care STDS; 2004 Jan; 18(1):7-14. PubMed ID: 15006189
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature.
Walensky RP; Ciaranello AL; Park JE; Freedberg KA
Clin Infect Dis; 2010 Jul; 51(1):85-92. PubMed ID: 20482371
[TBL] [Abstract][Full Text] [Related]
19. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
Elliott JH; Lynen L; Calmy A; De Luca A; Shafer RW; Zolfo M; Clotet B; Huffam S; Boucher CA; Cooper DA; Schapiro JM
AIDS; 2008 Oct; 22(16):2053-67. PubMed ID: 18753937
[No Abstract] [Full Text] [Related]
20. Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.
Nozza S; Galli L; Bigoloni A; Nicola G; Pogliaghi M; Cossarini F; Salpietro S; Galli A; Della Torre L; Tambussi G; Lazzarin A; Castagna A
J Acquir Immune Defic Syndr; 2011 Apr; 56(4):e113-5. PubMed ID: 21350358
[No Abstract] [Full Text] [Related]
[Next] [New Search]
